• Advanced BioDesign participation santé

    ADVANCED BIODESIGN (ABD)

    HEALTH PARTICIPATION
Advanced BioDesign ABD health participation

INVESTMENT YEAR: 2013
www.a-biodesign.com

Advanced BioDesign (ABD) is developing a new drug for the treatment of cancers resistant to current therapies. The mechanism of action of this synthetic compound constitutes a technological breakthrough in the means of treating cancer


SEFALDIN (cancer treatment)

ABD, having acquired a unique expertise in the field of cancer, is developing a new cancer treatment therapy. This program, known as SEFALDIN, has proven that it is possible to achieve targeted destruction of cancer cells by restoring the mechanisms for apoptosis that they have escaped by becoming malignant. The originality of the synthetic compound developed by ABD(Dimate) resides in its action on the detoxification mechanisms present in cancer cells.

The first cancer model chosen for this project is acute myeloid leukemia (AML), one of the most challenging cancers. In vitro studies have also validated Dimate’s therapeutic efficacy on aggressive solid tumor models (more than 230 to date) and particularly on resistant lines such as triple negative breast cancer and lung cancer.

Proof of concept has been extended in animal models for AML, melanoma and lung cancer and is in the process of validation for lymphoma, osteosarcoma, breast, pancreatic and colon cancer models.

SEFALDIN nouvelle thérapie pour le traitement du cancer

Mouse with lung cancer without treatment

Mouse after 24 days of treatment with Dimate

OUR PARTICIPATIONS

Xerys

XERYS FRANCE

7 rue d’Aguesseau

75008 Paris - France

+33 (0)1 82 52 12 25

FOLLOW-US: